John Temperato Biography and Net Worth

CEO of 9 Meters Biopharma

Mr. Temperato is an industry veteran with a wealth of gastrointestinal (GI) focused experience in both the operational and commercial aspects of the business. Prior to joining RDD, John held various leadership roles including, President & Chief Operating Officer/Chief Commercial Officer with Melinta Therapeutics, and Senior Vice President of Sales and Managed Markets with Salix Pharmaceuticals. Notably, at Salix Pharmaceuticals (Salix), Mr. Temperato played a critical role in the successful commercialization and growth of their broad GI portfolio and executed over ten launches during his tenure at the company driving growth of company revenues from $119 million in 2004 to $2 billion in 2015, when Salix was acquired by Bausch Health (NYSE: BHC) for ~$16 B. Across his career, John has been instrumental in defining and executing capital efficient go-to-market strategies, business development strategy and overseeing the commercialization and life-cycle management for small molecules, devices, and biologics. Additionally, he has developed strategies for reimbursement and external healthcare policy. John also brings with him extensive financial strategy and investor relations experience.

What is John Temperato's net worth?: The estimated net worth of John Temperato is at least $0.00 as of July 6th, 2022. Mr. Temperato owns 1,427,522 shares of 9 Meters Biopharma stock worth more than $0 as of November 21st. This net worth approximation does not reflect any other investments that Mr. Temperato may own. Learn More about John Temperato's net worth.
How do I contact John Temperato?: The corporate mailing address for Mr. Temperato and other 9 Meters Biopharma executives is 8480 HONEYCUTT ROAD SUITE 120, RALEIGH NC, 27615. 9 Meters Biopharma can also be reached via phone at (919) 275-1933 and via email at [email protected]. Learn More on John Temperato's contact information.
Has John Temperato been buying or selling shares of 9 Meters Biopharma?: John Temperato has not been actively trading shares of 9 Meters Biopharma over the course of the past ninety days. Most recently, on Wednesday, July 6th, John Temperato bought 125,000 shares of 9 Meters Biopharma stock. The stock was acquired at an average cost of $0.23 per share, with a total value of $28,750.00. Following the completion of the transaction, the chief executive officer now directly owns 1,427,522 shares of the company's stock, valued at $328,330.06. Learn More on John Temperato's trading history.
Who are 9 Meters Biopharma's active insiders?: 9 Meters Biopharma's insider roster includes Michael Constantino (Director), Mark Sirgo (Director), Edward Sitar (CFO), and John Temperato (CEO). Learn More on 9 Meters Biopharma's active insiders.

John Temperato Insider Trading History at 9 Meters Biopharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/6/2022	Buy	125,000	$0.23	$28,750.00	1,427,522
3/3/2022	Buy	100,000	$0.56	$56,000.00
11/18/2021	Buy	50,000	$1.05	$52,500.00
8/18/2021	Buy	25,000	$1.05	$26,250.00	1,102,522
4/5/2021	Buy	100,000	$1.00	$100,000.00	1,077,522
8/21/2020	Buy	70,000	$0.69	$48,300.00	615,496
8/17/2020	Buy	35,000	$0.57	$19,950.00	545,496
6/15/2020	Buy	10,000	$0.60	$6,000.00

John Temperato Buying and Selling Activity at 9 Meters Biopharma

9 Meters Biopharma Company Overview

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.

Today's Range

Now: N/A

50 Day Range

MA: N/A

2 Week Range

Now: N/A

Volume

46 shs

Average Volume

315,915 shs

Market Capitalization

$1.04 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.36

Blackrock’s Sending THIS Crypto Higher on Purpose

From Crypto 101 Media | Ad

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

YES, I WANT THE #1 CRYPTO NOW